The Asia-Pacific Peptide Therapeutics Market will see a considerable growth of 6.7% during the forecast period. Asia-Pacific is one of the promising regions in the field of peptides. The frequent collaboration of various global and domestic companies through workshops and seminars is also expected to present a new growth opportunity for the Asia-Pacific Peptide Therapeutics Market.
‘AsiaTIDES Oligonucleotide & Peptide Therapeutics’ is expected to take place between November 11 to 13, 2020. It is the only event in Asia that is expected to bring together science, technologies, and partners to accelerate oligonucleotide and peptide molecules to market. It offers separate tracks covering the latest oligonucleotide and peptide development strategies from discovery, nonclinical, clinical, and CMC to late-stage development and commercialization.
A full report of Asia-Pacific Peptide Therapeutics Market is available at: https://www.omrglobal.com/industry-reports/asia-pacific-peptide-therapeutics-market
- Drug delivery of oligonucleotides, peptides, mRNA, RNA, and CRISPR
- CMC approaches to accelerate peptide, oligonucleotides, and mRNA therapeutics
- The future of peptide vaccines and personalized peptide therapies
Additionally, numerous global companies are also expanding their R&D centers across the region which will also aid the growing shares of the Peptide Therapeutics Market in Asia-Pacific. The global market
players are expanding their reach in the emerging economies of the region, especially in India, China, Vietnam, and Indonesia. With this expansion, the market for peptide therapeutics is expected to increase in Asia-Pacific during the forecast period.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-peptide-therapeutics-market
Market Coverage
- Study Period- 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segments Covered- By Route of Administration and By Application
- Countries Covered- China, Japan, India, Rest of Asia-Pacific
- Key Companies Profiled- Novo Nordisk A/S, Eli Lilly & Co., Amgen Inc., Astellas Pharma Inc., Teva Pharmaceuticals Industries Ltd., and Takeda Pharmaceutical Co. Ltd.
Key questions addressed by the report
- What is the market growth rate during the forecast period?
- Which segment/region dominates the market in the base year?
- Which segment/region will project the fastest growth in the market during the forecast period?
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Asia-Pacific Peptide Therapeutics Market – Segmentation
By Route of Administration
- Oral
- Parenteral
By Application
- Cancer
- Gastrointestinal Disorders
- Central Nervous System Disorders
- Respiratory Disorders
- Others
This release has been published on Next Biz Post. Next Biz Post is not responsible for any content included in this release.
